|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
SELECT PUBLICATIONS
Burris H III et al. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 2004;22(9):1621-9. Abstract
Joensuu H et al; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20. Abstract
Perez EA. Advances in monoclonal antibody therapy for breast cancer: Further analysis of NCCTG-N9831. Presentation. ASCO 2005. Late-Breaking Scientific Symposium. No abstract available
Piccart-Gebhart MJ et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER 2-positive breast cancer. N Engl J Med 2005;353(16):1659-72. Abstract
Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER 2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract
Slamon D et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide
followed by docetaxel (AC
T) with doxorubicin and cyclophosphamide
followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and
trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study.
Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 1.
Tan-Chiu E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23(31):7811-9. Abstract
 |
 |
